Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of ...
Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...
Credit: Getty Images. ADX-2191 is a preservative-free, intravitreal formulation of methotrexate designed to be vitreous-compatible. The New Drug Application (NDA) for ADX-2191 (methotrexate injection) ...
INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback